Immunotherapies that target programmed cell death-ligand 1 (PD-L1) or programmed cell death-1 (PD-1) inhibitors have become cornerstones of treatments for malignant tumours such as gastrointestinal, pulmonary, renal cell carcinoma, and melanoma [2–5]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.